ArticleThe American journal of pathology2001
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 214 citations in OpenAlex.
- Hypoxia and oxidative stress related to inflammation and vascular aspects of the pathogenesis of psoriasis.Skin health and disease · 2026Review
- Loss of Fibronectin Fiber Tension in Glioblastoma is Associated with Microvascular Proliferations and Immune Cell Infiltration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer.Scientific reports · 2023Article
- Vascular co-option in resistance to anti-angiogenic therapy.Frontiers in oncology · 2023Review
- Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.The Journal of clinical investigation · 2022Article
- An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Fibrin-based factor delivery for therapeutic angiogenesis: friend or foe?Cell and tissue research · 2022Review
- Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma.Frontiers in oncology · 2022Review
- Review
- Response to Michiel Alexander de Raaf et al.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- Deficiency of MFSD7c results in microcephaly-associated vasculopathy in Fowler syndrome.The Journal of clinical investigation · 2020Article
- A novel rat model of pulmonary hypertension induced by mono treatment with SU5416.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Article
- Therapeutic vascularization in regenerative medicine.Stem cells translational medicine · 2020Review
- RECK in Neural Precursor Cells Plays a Critical Role in Mouse Forebrain Angiogenesis.iScience · 2019Article
- Article
- CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via AThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Salvianolic acid A inhibits tumor-associated angiogenesis by blocking GRP78 secretion.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Inspired by Nature: Hydrogels as Versatile Tools for Vascular Engineering.Advances in wound care · 2018Review
- Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma.Cancer biology & therapy · 2018Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Glomeruloid bodies are a defining histological feature of glioblastoma multiforme and some other tumors and vascular malformations. Little is known about their pathogenesis. We injected a nonreplicating adenoviral vector engineered to express vascular permeability factor/vascular endothelial growth factor-164 (VPF/VEGF(164)) into the ears of athymic mice. This vector infected local cells that strongly expressed VPF/VEGF(164) mRNA for 10 to 14 days, after which expression gradually declined. Locally expressed VPF/VEGF(164) induced an early increase in microvascular permeability, leading within 24 hours to edema and deposition of extravascular fibrin; in addition, many pre-existing microvessels enlarged to form thin-walled, pericyte-poor, "mother" vessels. Glomeruloid body precursors were first detected at 3 days as focal accumulations of rapidly proliferating cells in the endothelial lining of mother vessels, immediately adjacent to cells expressing VPF/VEGF(164). Initially, glomeruloid bodies were comprised of endothelial cells but subsequently pericytes and macrophages also participated. As they enlarged by endothelial cell and pericyte proliferation, glomeruloid bodies severely compromised mother vessel lumens and blood flow. Subsequently, as VPF/VEGF(164) expression declined, glomeruloid bodies devolved throughout a period of weeks by apoptosis and reorganization into normal-appearing microvessels. These results provide the first animal model for inducing glomeruloid bodies and indicate that VPF/VEGF(164) is sufficient for their induction and necessary for their maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.